Status:
COMPLETED
Cardiac Amyloidosis Prevalence and Outcome in Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Implantation
Lead Sponsor:
CHU de Reims
Conditions:
Aortic Stenosis
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
Aortic stenosis (AS) is the most frequent valvulopathy in the general population in France and more generally in developed countries, due to populations aging. Its standard treatment is historically s...
Detailed Description
The aim of the study is to describe prevalence of cardiac amyloidosis with transthyretin in patients undergoing transcatheter aortic valve implantation.
Eligibility Criteria
Inclusion
- inclusion criteria :
- patients over 60 years old
- Patients admitted in Reims university cardiology department for per-cutaneous aortic valve replacement due to severe aortic stenosis
- Patients enrolled in the national healthcare insurance program
- Patients consenting to participate to the study
- exclusion criteria :
- \- AL amyloïdosis patients
Exclusion
Key Trial Info
Start Date :
December 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 16 2022
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT05384418
Start Date
December 9 2020
End Date
September 16 2022
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France